For research and educational purposes only. Not medical advice.
Pramlintide Reference
Educational, not medical advice reference for Pramlintide: Hormonal, Metabolic; regulatory status, evidence posture, source review, and schedule…
Reference summary
Pramlintide is a label-verified synthetic amylin analog and the precursor product that informed Novo Nordisk's long-acting amylin development (cagrilintide and CagriSema). The Ratner 2004 Diabet Med long-term RCT (PMID 15498087) demonstrated improvements in HbA1c and weight in type 1 diabetes patients on insulin when pramlintide was added as a mealtime adjunct. The label-verified mealtime regimens for T1DM (15 to 60 mcg) and T2DM (60 to 120 mcg) are the routine clinical reference.
Regulatory and posture
- Categories
- Hormonal, Metabolic
- Aliases
- Symlin, Synthetic amylin analog (the precursor to long-acting cagrilintide)
- Evidence posture
- human
- Regulatory status
- FDA-approved prescription medication (Symlin, 2005). Indicated as an adjunct mealtime therapy in patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve glycemic control. Boxed warning for severe insulin-induced hypoglycemia.
- Content review status
- label verified
Selected public sources
- DailyMed pramlintide (Symlin) prescribing information
- PubMed: Ratner et al. Diabet Med 2004 - amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes (PMID 15498087)
Related tools
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.